Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
Madrid-based plant extract producer Natac Group has received a GMP quality certificate from the Spanish Agency of Medicines and Medical Products, allowing the company to make active ingredients for the pharma industry...
read more
OncoZenge says it plans to partner with Pharmanovia, regarding commercialization rights for its oral lozenge formulation of bupivacaine, BupiZenge, in Europe, the Middle East and Northern Africa...
read more
French government blessing in hand, Sanofi enters exclusive negotiations to sell a controlling stake in Opella in a deal worth over $16 billion...
read more
Amneal has received U.S. FDA approval for its pyridostigmine bromide extended-release tablets indicated for pretreatment against the lethal effects of soman nerve agent poisoning...
read more
Vaxart will present research on its phase 2 COVID and norovirus oral tablet vaccine candidates at the World Vaccine Congress Europe.
read more
Orlynvah is the first FDA-approved product for Dublin-based Iterum, and the first oral penem approved in the U.S.
read more
Merck has acquired Yale University spinout company Modifi Biosciences, picking up a preclinical glioblastoma asset in a deal that could reach $1.3 billion.
read more
Rectify Pharmaceuticals has selected a lead positive functional modulator and is advancing to first-in-human clinical trials for primary sclerosing cholangitis.
read more
Protega has won U.S. FDA approval for a 10 mg immediate-release version of its RoxyBond pain management tablet featuring abuse-deterrent technology.
read more
The decision in the patent infringement lawsuit filed by Incyte will delay Sun's U.S. launch of Leqselvi.
read more
Axonis will use proceeds from an oversubscribed Series A financing round towards advancing its lead development candidate, an oral therapeutic for KCC2.
read more
Viking shared promising clinical data from the company's obesity program at ObesityWeek 2024, highlighting both its tablet and subcutaneous formulations.
read more
Journey says that Emrosi could offer a new standard of care in rosacea treatment.
read more
Novo Nordisk will terminate the development of ocedurenone following a trial fail and $816 million loss.
read more
Citing efficacy data, the FDA has proposed removing the country's most popular oral nasal decongestant ingredient.
read more